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Abstract: In cervical cancer screening program of Latina (Italy) the hr-HPV as primary test is performed only on wom-
en aged 35-64 while women aged 25-34 are invited to perform PapTest. The aim of this study was to evaluate the 
impact of the application of the PapTest in women aged 25-34 and to evaluate the management of ASCUS. Women 
aged 25-34 were invited to perform PapTest according to the Italian guidelines; women with diagnosis of LSIL+ were 
referred to colposcopy while women with diagnosis of ASCUS were referred to hr-HPV test and only women resulted 
positive were referred to colposcopy. The 4.0% of women resulted positive to PapTest and the referral rate to colpos-
copy was 3.5%. The PPV value for CIN2+ at colposcopy was 7.2% and the Detection Rate (DR) for CIN2+ was 2.40‰. 
The ASCUS category was diagnosed in 41.8% of women resulted positive to PapTest and between them the 70.6% 
resulted positive to the hr-HPV test. The referral rate to colposcopy of women resulted positive to hr-HPV test was 
1.1%. The PPV for CIN2+ at colposcopy and the DR of CIN2+ was 8.4% and 0.96‰ respectively. Between women 
with diagnosis of ASCUS, only 6 women showed a CIN2+ lesion (4 CIN2 and 2 CIN3). The present study showed 
that this algorithm, applied to women aged 25-34, obtained a good performance in term of test specificity (98%) 
and confirm that the application of hr-HPV test in the management of ASCUS leads to a decreased of inappropriate 
colposcopy due to transitory infection in young women.
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Introduction 
The necessary condition so that cervical can-
cer can be developed is the persistent infection 
with an oncogenic human papillomavirus (HPV) 
type described as high-risk-HPV (hr-HPV) [1]. 
The hr-HPV test is a screening test to define the 
presence of an hr-HPV type in a sample of exfo-
liated cervical cells [2, 3]. This is used in the 
Italian screening programme as a preventive 
medicine intervention aimed at early diagnosis 
and improvement of prognosis of cervical can-
cer [4]. The rationale of hr-HPV test as a prima-
ry test with cytological triage is to perform 
before the more sensitive test and then the 
more specific test, in order to anticipate the 
diagnosis and to not increase the over-diagno-
sis of intraepithelial lesions [5-7]. It’s well 
established that there is a high prevalence of 
HPV infection in young women, when they 
became sexually active, that tends to decrease 
with increasing of age [8] and in most cases, 
the infection caused by oncogenic HPV sub-
type, regresses spontaneously [9]; moreover, 
excisional treatment of cervical lesions is asso-
ciated with increased risk of pregnancy-related 
morbidity and mortality [10].
Effectively, the NTCC (New Technologies for 
Cervical Cancer ) study showed that the use of 
hr-HPV test applied to young women (aged 
25-34) resulted in over-diagnosis and in in- 
crease of unnecessary treatment of regre- 
ssive CIN2+ lesions (cervical intraepithelial 
neoplasia) [5, 6]. Therefore, the GISCi (Italian 
Association of Cervical Screening Programs) 
guidelines recommended to not carry out hr-
HPV test before of 35 years of age and so to 
perform PapTest to women aged 25-34 [4]. 
Successively, the women (aged 25-34) with 
diagnosis of Low-grade Squamous Intraepithe- 
lial Lesion or worse (LSIL+) are referred to col-
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poscopy while women with diagnosis of ASCUS 
(Atypical Squamous Cells of Undetermined 
Significance) are referred to hr-HPV test and 
only women resulted positive to the molecular 
test were referred to colposcopy, otherwise 
women are recalled after three years as well as 
women with a negative PapTest (Figure 1). The 
triage of ASCUS with the hr-HPV test arises with 
the aim to discriminate between women with 
cytological abnormalities that are precursor of 
a lesion and benign alterations [11]. 
We aim to evaluate the outcome and impact of 
the application of the PapTest as a primary test 
and in particularly to evaluate the management 
of ASCUS in women aged 25-34 using data of 3 
years (2012-2014) of the screening centre of 
Latina (Italy). 
Materials and methods
Study population
Study populations have been enrolled by the 
Pathology Unit of ICOT Hospital, Department of 
Medical-Surgical Sciences and Bio-echnolo- 
gies, Sapienza University of Rome and 
Screening Unit of Local Health Unit of Latina. 
From 2012 in the Latina district it was organ-
ized a new cervical screening; this program 
considers that women aged 25-34 are invited 
by mail to perform a PapTest (Figure 1) while 
women aged 35-64 are invited by mail to per-
form hr-HPV test according to GISCi algorithm 
[4, 12].
In this study we evaluate women aged 25-34 
that were invited to perform a PapTest from 
April 2012 to December 2014. Cytological and 
histological diagnosis were reported according 
to 2001 Bethesda System [13] evaluated by 
one cytologist and two pathologists. Women 
with diagnosis of ASCUS were referred to hr-
HPV test. The women resulted negative to hr-
HPV test were recalled after three years as well 
as women resulted negative to PapTest. Indeed, 
women with diagnosis of LSIL+ or that resulted 
positive to hr-HPV test were referred to 
colposcopy.
The colposcopy was performed by two gynae-
cologists of the screening unit while colposcopy 
biopsies were read by two pathologist and 
women with diagnosis of CIN2 or more severe 
(CIN2+) were referred to excisional treatment.
Cytology: PapTest
The cervical cell samples were obtained by 
using a cytobrush and were put in PreservCyt 
solution; liquid-based cytology was performed 
by using the Sure Path system (BD SurePathTM, 
Franklin Lakes, NJ, USA). One slide per woman 
was prepared according to the supplier’s 
instructions.
Hybrid capture 2 high-risk HPV DNA test (HC2)
Exfoliated cervical cells were collected using a 
cytobrush and eluted in the Sample Transport 
Medium (STM, Qiagen, Hilden, DE). Cervical 
specimens were denatured to disrupt the virus 
and release the target DNA. The RNA probes 
were diluted in a probe diluent and once loaded 
all the samples, calibrators, controls and rea-
gents, the hybridization phase began according 
to supplier’s instructions. The chemilumines-
cent reaction was measured by luminometer 
(DML instrument, Qiagen, Hilden, DE) and the 
emitted light was measured as RLU.
For each reaction were used three negative 
controls, three positive controls, one quality 
control for low-risk HPV (lr-HPV) and one quality 
control for hr-HPV. Samples that showed a RLU 
≥ 1 pg/ml were considered positive. 
Results
In the period of reference (April 2012 - De- 
cember 2014) were enrolled 15,0517 women 
aged 25-64 and 44,415 (29.5%) were screened. 
Between them, 41,092 (27.3%) aged 25-34 
and 6,249 (15.2%) were screened.
Between the women aged 25-34 the 4.0% 
(251/6249) resulted positive to PapTest 
(ASCUS or worse: ASCUS+) and the most fre-
Figure 1. Algorithm of the cervical cancer screening 
program of women aged 25-34 in Latina district.
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Table 1. Results of the screening test performance of the HPV screening program of women aged 25-34
2012 % ‰ 2013 % ‰ 2014 % ‰ Total % ‰
Women Invitedaged 25-34 11484   14013   15595   41092   
Women Examinated 299/11484 2.6  2831/14013 20.2  3119/15595 20  6249/41092 15.2  
Proportion of positive PapTest 22/299 7.4  121/2831 4.3  108/3119 3.5  251/6249 4.0  
    ASCUS 12/22 54.5 49/121 40.5 44/108 40.7 105/251 41.8
    LSIL 8/22 36.4 65/49 53.7 57/44 52.8 130/251 51.8
    ASCH 0/22 0 2/49 1.7 2/44 1.9 4/251 1.6
    HSIL 2/22 9.1  4/49 3.3  5/44 4.6  11/251 4.4  
Referral rate to colposcopy 19/299 6.4  112/2831 4.0  87/3119 2.8  218/6449 3.5  
Compliance with referral to colposcopy 18/19 94.7  106/112 94.6  85/87 97.7  209/218 95.9  
PPV for CIN2+ 1/18 5.6  8/106 7.6  6/85 7.0  15/209 7.2  
Detection rate for CIN2+ 1/299  3.34  8/2831  2.83 6/3119  1.92 15/6249  2.40
Table 3. Results of the screening test performance of the HPV screening program of women aged 25-34 with diagnosis of ASCUS
2012 % ‰ 2013 % ‰ 2014 % ‰ Total % ‰
Women Examinatedaged 25-34 299/11484 2.6  2831/14013 20.2  3119/15595 20  6249/41092 15.2  
Proportion of ASCUS 12/22 54.5  49/121 40.5  44/108 40.7  105/251 41.8  
Proportion of positive hr-HPV test 9/11 81.8  40/49 81.6  23/42 54.8  72/102 70.6  
Referral rate to colposcopy 9/299 3.0  40/2831 1.4  23/3119 0.7  72/6249 1.1  
Compliance with referral to colposcopy 9/9 100  39/40 97.5  23/23 100  71/72 98.6  
PPV for CIN2+ 1/9 11.1  2/39 5.1   3/23 13.0  6/71 8.4  
Detection rate for CIN2+ 1/299  3.34 2/2831  0.71 3/3119  0.96 6/6249  0.96
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quent diagnostic category was LSIL (51.8%, 
130/251) followed by ASCUS (41.8%, 105/251), 
HSIL (High grade Squamous Intraepithelial 
lesion, 4.4%, 11/251) and ASCH (Atypical 
Squamous Cell, High-grade not excluded, 1.6%, 
4/251). The PapTest positive rate decreased 
from 2012 (7.4%) to 2014 (3.5%) and the fre-
quency of diagnostic category was similar in 
2013 and 2014; indeed, the most frequent 
diagnostic category was LSIL in 2013 (53.7%, 
65/121) and 2014 (52.8%, 57/108) while was 
ASCUS in 2012 (54.5%, 12/22). The referral 
rate to colposcopy was 3.5% with a decrease 
during the three years (6.4%, 4% and 2.8%). 
During these three years the adhesion to col-
poscopy was 95.9% (Table 1). The positive pre-
dictive value (PPV) for CIN2+ at colposcopy was 
similar during 2013 and 2014 (7.6% and 7.0%) 
while during 2012 this value was lower (5.6%); 
however in average, the PPV value for CIN2+ at 
colposcopy was 7.2%. The detection rate (DR) 
for CIN2+ was 2.40‰ with a decrease from 
2012 to 2014 (3.34‰, 2.83‰ and 1.92‰ 
respectively, Table 1). The most frequent histl- 
ogical category was CIN1 (82.1%) followed by 
CIN3 (6.0%) and CIN2 (5.2%) and even taking 
into account year by year the most frequent cat-
egory was CIN1 (Table 2). The referral rate to 
next round (after three years) was 96.5% with a 
decrease during the first three years. The speci-
ficity value of this algorithm in women aged 
25-64 was 98.2% with the same value during 
the first three years.
The ASCUS category was diagnosed in 41.8% 
(105/251) of women resulted positive to 
PapTest; this value was similar in 2013 and 
2014 (40.5% and 40.7%) while was higher in 
2012 (54.5%). The hr-HPV positive rate among 
women with diagnosis of ASCUS was 70.6% 
(72/102) and this rate was similar in the first 
two years (81.8% and 81.6%) while was lower in 
2014 (54.8%). The referral rate to colposcopy 
of women resulted positive to hr-HPV test was 
1.1% with a decrease during the three years 
(3.0%, 1.4% and 0.7%). There 
was a maximum adhesion 
to colposcopy in 2012 and 
2014 while in 2013 the adhe-
sion to colposcopy was 97.5% 
with an average of 98.6%. 
The ASCUS PPV for CIN2+ at 
colposcopy was 8.4% and 
we observed different value 
among these period: 11.1%, 5.1% and 13% in 
2012, 2013 and 2014 respectively. The ASCUS 
DR of CIN2+ relative to the total was 0.96‰; 
this value was similar in 2013 and 2014 (0.71‰ 
and 0.96‰) while was higher in 2012 (3.34‰, 
Table 3). Only a small number of CIN2+ lesions 
were diagnosed during this period: 4 CIN2 and 
2 CIN3 lesions between women with diagnosis 
of ASCUS.
Discussion
Most HPV infections regress spontaneously 
and only a minority become persistent and pro-
gress in cancer lesion [9]. It has been showed 
that the molecular hr-HPV test is more sensitive 
than PapTest in identifying CIN2+ lesions but 
less specific; so, the application of this test to 
women aged 25-34 resulted in over-diagnosis 
and in increase of unnecessary treatment of 
regressive CIN2+ lesions [5-7]. In this study we 
applied the Italian guideline in the screening of 
cervical cancer [4] and we performed only 
PapTest to women aged 25-34 and performed 
the hr-HPV test for the triage of ASCUS catego-
ry. The acceptance rate to perform PapTest was 
lower than the acceptance rate to perform hr-
HPV test between women aged 35-64 while the 
adhesion to colposcopy value was equal to 
women aged 35-64 [12].
The PapTest positive rate (ASCUS+, 4.0%) was 
equal to the value observed in NTCC study per-
formed on women of the same age (4.1%) [5, 
6]. In our study we observed that the most fre-
quently diagnosed category was LSIL (2.1%) 
unlike NTCC study [5, 6] where the most fre-
quently represented category was ASCUS with 
a positive rate of 2.0%, value that is anyway 
below the limits set by the GISCi guidelines 
(<5%) [4]. Indeed, the ASCUS category includes 
women that are a low risk of developing a 
CIN2+ lesion and it doesn’t describe a real 
diagnostic entity but rather includes morpho-
logical changes that are suggestive of squa-
Table 2. Results of histological diagnosis
Histological 
diagnosis
 2012 % 2013 % 2014 % Total %
CIN1 12/14 85.7 56/69 81.2 42/51 82.3 110/134 82.1
CIN2 1/14 7.1 4/69 5.8 2/51 3.9 7/13 5.2
CIN3 0/14 0  4/69 5.8 4/51 7.4 8/134 6.0
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mous intraephitelial lesion of low/indetermi-
nate grade and that be confused with altera-
tions of reactive, inflammatory and metaplastic 
nature [14] and for these reasons its interpreta-
tions is highly variable across the pathologists 
[15].
In our study the triage of ASCUS category, 
through the hr-HPV test, showed that the 71% 
of women with diagnosis of ASCUS presented 
were infected with the hr-HPV and this value 
was higher than NTCC study that include 
ASCUS+ category (60.6%) [16].
Indeed, considering only the ASCUS category, 
the referral rate to colposcopy (1.1%) was lower 
than the referral rate to colposcopy referred to 
the total population of young women (3.5%) and 
this value is consistent with NTCC study (4%) [5, 
6].
The predictive positive value (PPV) for CIN2+ of 
women aged 25-34 was 7.2% and this value is 
lower than NTCC study (9%) [5, 6] while the PPV 
referred only to the ASCUS category was 8.4%. 
The DR of CIN2+ referred to the total popula-
tion (2.4‰) was equal to the NTCC study [5, 6] 
while the ASCUS DR of CIN2+ was lower 
(0.96%).
Finally, the present study showed that this algo-
rithm, applied to women aged 25-34, obtained 
a good performance in term of test specificity 
(98%). Moreover, this study confirm that the 
employment of hr-HPV test in the management 
of ASCUS can help the operators to confirm a 
cytological abnormalities caused by an HPV 
infection and to avoid unnecessary colposcopy 
in women aged 25-34.
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